NIQ Debuts Growth Pathways: Transforming How Brands Create Growth
9.4.2026 13:00:00 CEST | Business Wire | Press Release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, announces the launch of NIQ Growth Pathways, a next-generation insights and analytics offering that modernizes traditional research and gives business leaders and marketers a clearer and structured route for category and brand growth. By integrating qualitative and quantitative research with NIQ’s industry-leading performance data, Growth Pathways delivers a connected view of how consumers think, feel, and act.
In today’s shifting consumer landscape, where global CPG volume growth has stagnated at under 1% annually, brand marketers need clarity on where to source demand, which opportunities matter most, and how to focus resources that will accelerate penetration and strengthen brand preference. Traditional strategies no longer meet the needs of today’s environment, as consumer behavior evolves and market dynamics grow increasingly complex.
NIQ’s Growth Pathways creates a growth relevant roadmap relevant for your brand and your market context, by linking your current performance reality – your actual sales performance, with consumer insights and future performance projections, into an expedited and actionable roadmap to achieve market growth. Fast AI enabled qualitative research at scale reveals the real, lived human Jobs to Be Done and behavioral context that sit behind category and brand choice. This provides an accurate starting point for sizing and prioritizing the high-value strategic spaces where your brand has the right-to-play. This all comes together as a strategic playbook for either category, or brand growth, or both.
“When brands look beyond familiar boundaries and consider the full range of choices consumers actually weigh in and beyond your category, new growth possibilities come into view,” said Stacy Bereck, NIQ Global Practice Leader. “Growth Pathways helps teams notice opportunities in places they may not have explored previously, which inspires new ways of thinking about growth. As brands innovate and enter new spaces, they can energize the entire category.”
The launch of Growth Pathways reflects NIQ’s ongoing transformation and commitment to delivering AI-enabled, open-data, client-first solutions. With more than 23,000 clients across 90+ countries, 22.2M store coverage, 220M product categories and collaboration programs across more than 50 retailers worldwide, NIQ continues to build a faster, smarter, and more connected insights ecosystem—empowering leaders with predictive intelligence that fuels growth across the global marketplace.
“More than ever before, companies need to make fewer but bigger brand bets in order to grow, and those bets must be consumer driven, evidence-based, and scalable,” said Gillian O'Sullivan, NIQ Global Sub-Practice Leader. “Growth Pathways takes validated marketing methods and applies them in a structured scientific KPI framework to determine the right pathway to sizeable and sustainable brand growth.”
To explore NIQ Growth Pathways or request a demo, click here.
FAQs
1. What is NIQ Growth Pathways?
NIQ Growth Pathways is an AI-enabled consumer insights and analytics solution that helps brands identify, prioritize, and activate new sources of growth. It combines consumer research, retail measurement data, and advanced analytics to deliver a structured growth strategy for brands and categories.
2. What does NIQ Growth Pathways do?
NIQ Growth Pathways helps companies:
- Identify untapped growth opportunities
- Understand consumer behavior (what consumers think, feel, and do)
- Prioritize high-value demand spaces
- Build actionable growth strategies based on data
It translates complex data into clear, decision-ready growth pathways.
3. How does NIQ Growth Pathways use AI?
NIQ Growth Pathways uses AI to scale qualitative research and uncover deep consumer insights, including motivations, unmet needs, and “Jobs to Be Done.” AI accelerates insight generation, improves accuracy, and enables faster identification of growth opportunities.
4. What makes NIQ Growth Pathways different from traditional market research?
Unlike traditional market research, NIQ Growth Pathways:
- Integrates qualitative insights, quantitative data, and sales performance
- Connects past performance with future growth projections
- Uses AI to analyze consumer behavior at scale
- Delivers a structured, actionable growth roadmap instead of static reports
5. What problem does NIQ Growth Pathways solve for brands?
NIQ Growth Pathways helps brands solve the problem of low growth and unclear demand signals in modern markets. With global CPG growth under 1%, brands need better tools to identify where to grow, how to win, and which investments will deliver the highest return.
6. Who should use NIQ Growth Pathways?
NIQ Growth Pathways is designed for:
- Brand managers
- Marketing leaders
- Consumer insights teams
- Strategy and innovation teams
It is especially useful for organizations making large, strategic, data-driven growth decisions.
7. What industries can use NIQ Growth Pathways?
NIQ Growth Pathways is primarily built for FMCG and CPG companies but can be applied to any consumer-focused industry that relies on understanding buying behavior, demand drivers, and market dynamics.
8. What are “growth pathways” in NIQ Growth Pathways?
“Growth pathways” are data-driven, prioritized routes to growth. They are based on:
- Current brand and category performance
- Consumer needs and behaviors
- Competitive and market dynamics
- Future growth potential
Each pathway represents a strategic opportunity that a brand can act on.
9. How does NIQ Growth Pathways identify growth opportunities?
NIQ Growth Pathways identifies growth opportunities by combining:
- Retail and sales performance data
- Consumer research (qualitative and quantitative)
- AI-driven insight generation
- Advanced analytics
This creates a holistic view of where demand exists and where it can be expanded.
10. How does NIQ Growth Pathways help brands grow beyond their category?
NIQ Growth Pathways analyzes the full set of consumer choices, not just those within a single category. This helps brands discover adjacent markets, new use cases, and emerging white spaces where they have the right to compete and grow.
11. What are the key benefits of NIQ Growth Pathways?
Key benefits include:
- Identification of new and untapped growth opportunities
- Faster, AI-powered insights
- Clear prioritization of strategic investments
- A structured, repeatable growth framework
- Alignment between insights, strategy, and execution
12. How does NIQ Growth Pathways fit into NIQ’s capabilities?
NIQ Growth Pathways is built on NIQ’s global data, AI, and analytics platform, including:
- Retail measurement and consumer panel data
- AI modeling and advanced analytics
- Global coverage across 90+ countries
- Insights across $7.4 trillion in consumer spend
13. When was NIQ Growth Pathways launched?
NIQ Growth Pathways was announced on April 9, 2026, as part of NIQ’s continued investment in AI-enabled, client-first innovation.
14. How can companies access NIQ Growth Pathways?
Companies can access NIQ Growth Pathways by contacting NIQ or requesting a demo through www.niq.com.
About NIQ
NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.
With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.
For more information, please visit www.niq.com.
Forward Looking Statement:
This press release on NIQ Growth Pathways may contain forward looking statements regarding anticipated consumer behaviors, market trends, and industry developments. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as “expects,” “anticipates,” “projects,” “believes,” “forecasts,” “plan,” “look ahead,” “indicates”, and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.
© 2026 Nielsen Consumer LLC. All Rights Reserved.
NIQ-GENERAL
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409909932/en/
Contacts
Media Contact:
NIQ:media.relations@niq.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom